PT-141 (Bremelanotide)
Performance & EnduranceA melanocortin receptor agonist that enhances sexual function and arousal in both men and women.
Key Benefits
- ✓Enhances sexual arousal and desire
- ✓Improves erectile function
- ✓Works through the CNS, not vascular system
- ✓Effective for both men and women
- ✓May help with HSDD in women
- ✓No direct effect on cardiovascular system
- ✓Can improve sexual satisfaction
Dosing Information
Detailed Protocol
Administered via subcutaneous injection or nasal spray. Should be taken 30-60 minutes before anticipated sexual activity. Effects can last 6-12 hours. Should not be used more than twice per week.
About PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide that was developed from Melanotan II. It is a melanocortin receptor agonist that works primarily on the MC3R and MC4R receptors in the central nervous system. Unlike PDE5 inhibitors (like Viagra), PT-141 works through the nervous system to promote sexual arousal and desire.
Research Notes
Clinical studies led to FDA approval of Bremelanotide (Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Research demonstrates effectiveness in both men and women for improving sexual function through central nervous system mechanisms.
Potential Side Effects
- •Nausea (common, usually mild)
- •Flushing
- •Headache
- •Increased blood pressure
- •Injection site reaction
Always consult with a healthcare professional before starting any peptide therapy.